By InvitationPhase 2

Theophylline for Treatment of Pseudohypoparathyroidism

United States34 participantsStarted 2020-05-22

Plain-language summary

Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature, hormone resistance and cognitive impairment. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, improve glucose tolerance and decrease hormone resistance in children and young adults.

Who can participate

Age range2 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. History of a seizure disorder unrelated to hypocalcemia
✕. History of a cardiac arrhythmia (not including bradycardia)
✕. Hepatic insufficiency including cirrhosis and acute hepatitis (AST or ALT \>3x upper limit of normal)
✕. Congestive heart failure
✕. Current cigarette use or alcohol abuse
✕. Pregnancy or intention to become pregnant during the next year
✕. Active peptic ulcer disease
✕. Current use of medications known to effect theophylline levels

What they're measuring

Adverse Events

Timeframe: 24 months

Trial details

NCT IDNCT04240821

SponsorJaclyn Tamaroff

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Pseudohypoparathyroidism trials